Menu

Biosimilars/General

Switching V19A17

Canada’s Prince Edward Island adopts biosimilars switching policy

Biosimilars/General | Posted 07/11/2023

Canada’s Prince Edward Island (PEI) becomes the 11th Canadian jurisdiction to announce the adoption of biosimilars switching policies. 

Cancer image015

ASCO policy statement on biosimilars and interchangeables in oncology updated

Biosimilars/General | Posted 24/10/2023

The American Society of Clinical Oncology (ASCO) has released a new policy statement on the use of biosimilar and interchangeable products in oncology.

The statement proposes guidance and recommendations for stakeholders, including manufacturers, payers, regulatory agencies, clinicians, and patients, to ensure equitable access to high-quality care and to address challenges to biosimilar uptake [1].

DNA-Helix Serendipity V13K22

Biosimilars approved in Japan

Biosimilars/General | Posted 07/03/2014

Last update: 24 October 2023

In Japan, the regulatory body for the approval of medicines, including biologicals, is the Ministry for Health Labour and Welfare (MHLW).

Biological 143606710 V14J14ct

Promotion of biosimilar product development in Puerto Rico

Biosimilars/General | Posted 17/10/2023

The Puerto Rico Economic Development Bank (Banco de Desarrollo Económico para Puerto Rico, BDE)announced in August 2023 a funding of US$3.85 million for Biosimilar Sciences PR, LLC (Biosimilar Sciences) and Ocyon Bio PR Inc (OcyonBio) to facilitate the purchase of specialized biotechnology equipment. This funding comes from the State Small Business Credit Initiative (SSBCI) of the US Treasury for Small Businesses.

15 AA010699

CVS’ Cordavis to launch Sandoz’s Hyrimoz (adalimumab)

Biosimilars/General | Posted 03/10/2023

In August 2023, CVS Health Corp announced it has launched a new company called Cordavis that will work directly with manufacturers to commercialize and co-produce biosimilar medicines for the US market.

Adalimumab V13F21

Coherus retracts AbbVie restraining order in Humira biosimilar dispute

Biosimilars/General | Posted 11/08/2023

Coherus BioSciences agreed to retract its restraining order against AbbVie in June 2023, an action taken to prevent AbbVie from terminating its Humira licence deal [1].

113 MD002138

Proposal to widen access to trastuzumab in New Zealand

Biosimilars/General | Posted 28/07/2023

In New Zealand there has been a proposal to widen access to intravenous trastuzumab from Herceptin to a biosimilar trastuzumab called Herzuma from 1 December 2023. 

136 AA011035

GADECCU position statement on biosimilars updated

Biosimilars/General | Posted 14/07/2023

GADECCU (Grupo Argentino de Enfermedad de Crohn y Colitis Ulcerosa), the Argentine Group for Crohn's Disease and Ulcerative Colitis, after providing key definitions on medical switch, non-medical switch and automatic substitution [1] and considering all the scientific information available, has updated its position in March 2023 regarding the use of biological medicines in clinical practice.

02 AA010638

GADECCU presents a new positioning on biosimilars

Biosimilars/General | Posted 13/06/2023

The Argentine Group for Crohn's Disease and Ulcerative Colitis (Grupo Argentino de Enfermedad de Crohn y Colitis Ulcerosa, GADECCU) has released an updated position statement on biosimilars, particularly regarding the alternate use of innovative biological drugs and biosimilars during the same chronic treatment in patients with inflammatory bowel disease.

FDA V17F30

Biosimilars approved in the US

Biosimilars/General | Posted 14/08/2015

Last update: 19 May 2023

In the US, a legal framework for approving biosimilars was established in 2009, via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).